Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Short-term Investments: 2017-2024

Historic Short-term Investments for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to $321.7 million.

  • Protagonist Therapeutics' Short-term Investments rose 36.97% to $462.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $462.4 million, marking a year-over-year increase of 36.97%. This contributed to the annual value of $321.7 million for FY2024, which is 107.68% up from last year.
  • Protagonist Therapeutics' Short-term Investments amounted to $321.7 million in FY2024, which was up 107.68% from $154.9 million recorded in FY2023.
  • Protagonist Therapeutics' Short-term Investments' 5-year high stood at $321.7 million during FY2024, with a 5-year trough of $111.6 million in FY2022.
  • For the 3-year period, Protagonist Therapeutics' Short-term Investments averaged around $196.1 million, with its median value being $154.9 million (2023).
  • In the last 5 years, Protagonist Therapeutics' Short-term Investments spiked by 1,884,900.00% in 2020 and then crashed by 45.08% in 2022.
  • Protagonist Therapeutics' Short-term Investments (Yearly) stood at $188.5 million in 2020, then climbed by 7.82% to $203.2 million in 2021, then tumbled by 45.08% to $111.6 million in 2022, then skyrocketed by 38.79% to $154.9 million in 2023, then soared by 107.68% to $321.7 million in 2024.